Feb 10, 2026 08:00AM
Jan 30, 2026 08:00AM
Jan 30, 2026 08:00AM
Jan 20, 2026 08:04AM
Jan 20, 2026 08:00AM
Jan 8, 2026 08:02AM
Jan 8, 2026 08:00AM Coya Therapeutics Announces Results of Investigator-Initiated Study of LD IL-2 and CTLA4-Ig Demonstrating Treg Enhancement and Cognitive Stability in Frontotemporal Dementia Patients
Jan 5, 2026 08:03AM
Jan 5, 2026 08:00AM
Dec 23, 2025 08:01AM
Dec 23, 2025 08:00AM
Dec 9, 2025 08:00AM
Nov 25, 2025 08:00AM
Nov 12, 2025 08:00AM Coya Therapeutics Reports Third Quarter Financial Results and Provides a Corporate Update
Oct 27, 2025 04:01PM
Oct 27, 2025 04:01PM
Oct 24, 2025 06:30AM
Oct 24, 2025 06:30AM
Oct 23, 2025 04:31PM
Oct 23, 2025 04:31PM
Sep 22, 2025 08:01AM Coya Therapeutics launches phase 2 ALS trial for COYA 302 treatment
Sep 22, 2025 08:00AM
Sep 4, 2025 08:03AM
Sep 4, 2025 08:00AM
Sep 3, 2025 11:50AM
Aug 25, 2025 08:00AM
Aug 25, 2025 06:42AM
Aug 25, 2025 05:22AM BTIG Reiterates Buy Rating on Coya Therapeutics (COYA)
Aug 12, 2025 08:00AM
Jul 24, 2025 08:15AM
Jul 24, 2025 08:15AM
Jul 22, 2025 08:15AM
Jun 18, 2025 08:15AM
Jun 2, 2025 08:02AM
Jun 2, 2025 08:00AM Coya Therapeutics Announces Issuance of New U.S. Patent Protecting Methods of Producing Recombinant Human (rh) Interleukin-2 (aldesleukin) Liquid Formulations
May 13, 2025 04:08PM
May 13, 2025 08:00AM
Mar 20, 2025 05:05AM
Mar 18, 2025 08:15AM
Feb 6, 2025 08:00AM
Feb 6, 2025 08:00AM
Dec 18, 2024 08:16AM Coya Therapeutics (COYA) Provides Enrollment Update of Phase 1 Study of Low Dose Interleukin-2 + CTLA4-Ig Fusion Protein
Dec 18, 2024 08:15AM
Nov 19, 2024 08:15AM
Nov 19, 2024 08:15AM
Nov 6, 2024 08:00AM
Nov 1, 2024 08:16AM
Nov 1, 2024 08:15AM
Oct 29, 2024 06:32AM Coya Therapeutics (COYA) Reports Positive Results of a Double-Blind Study of Subcutaneous Low-Dose Interleukin-2
Oct 29, 2024 06:30AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All